<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39391808</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2469-2964</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Pathogens &amp; immunity</Title><ISOAbbreviation>Pathog Immun</ISOAbbreviation></Journal><ArticleTitle>Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>11</EndPage><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.20411/pai.v10i1.752</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We isolated authentic JN.1.1, KP.1.1, LB.1, and KP.3.3 viruses and evaluated their sensitivity to neutralization by these mAbs in 2 target cell lines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Compared to ancestral strains, VYD222/Pemivibart remained moderately active against JN.1 subvariants, with a strong increase of 50% Inhibitory Concentration (IC50), reaching up to 3 to 15 µg/mL for KP3.3. AZD3152/Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP.1.1, LB.1, and KP3.3.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our results highlight the need for a close clinical monitoring of VYD222/Pemivibart and raise concerns about the clinical efficacy of AZD3152/Sipavibart.</AbstractText><CopyrightInformation>Copyright © 2024 Pathogens and Immunity.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Planas</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Research Institute, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staropoli</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Planchais</LastName><ForeName>Cyril</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Humoral Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yab</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Reference Center for Respiratory Viruses, Molecular Mechanisms of Multiplication of Pneumoviruses Unit, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeyarajah</LastName><ForeName>Banujaa</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Reference Center for Respiratory Viruses, Molecular Mechanisms of Multiplication of Pneumoviruses Unit, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahou</LastName><ForeName>Yannis</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Reference Center for Respiratory Viruses, Molecular Mechanisms of Multiplication of Pneumoviruses Unit, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prot</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guivel-Benhassine</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemoine</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bioinformatics and Biostatistics Hub, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enouf</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Reference Center for Respiratory Viruses, Molecular Mechanisms of Multiplication of Pneumoviruses Unit, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon-Loriere</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouquet</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Humoral Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rameix-Welti</LastName><ForeName>Marie-Anne</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>National Reference Center for Respiratory Viruses, Molecular Mechanisms of Multiplication of Pneumoviruses Unit, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Mechanisms of Multiplication of Pneumoviruses, Université Paris-Saclay, Université de Versailles St. Quentin, UMR 1173 (2I), INSERM; Assistance Publique des Hôpitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Research Institute, Créteil, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pathog Immun</MedlineTA><NlmUniqueID>101683909</NlmUniqueID><ISSNLinking>2469-2964</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pemivibart</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">Sipavibart</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">neutralization</Keyword></KeywordList><CoiStatement>CP, HM, and OS have a patent application for anti-SARS-CoV-2 monoclonal antibodies not used in the present study (PCT/FR2021/070522, WO 2022/228827A1), and HM is a scientific consultant for SpikImm biotech. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39391808</ArticleId><ArticleId IdType="pmc">PMC11464000</ArticleId><ArticleId IdType="doi">10.20411/pai.v10i1.752</ArticleId><ArticleId IdType="pii">pai.v10i1.752</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhas-sine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Bolland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Pere H, Lina B, Trouillet-Assant S, Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat Commun.
2024;15(1):2254. doi: 10.1038/s41467-024-46490-7. PubMed PMID: 38480689; PMCID: PMC10938001.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46490-7</ArticleId><ArticleId IdType="pmc">PMC10938001</ArticleId><ArticleId IdType="pubmed">38480689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku Y, Yo MS, Tolentino JE, Uriu K, Okumura K, Genotype to Phenotype Japan C, Ito J, Sato K. Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants. Lancet Infect Dis.
2024;24(8):e482–e3. doi: 10.1016/S1473-3099(24)00415-8. PubMed PMID: 38945150.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00415-8</ArticleId><ArticleId IdType="pubmed">38945150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku Y, Uriu K, Kosugi Y, Okumura K, Yamasoba D, Uwamino Y, Kuramochi J, Sadamasu K, Yoshimura K, Asakura H, Nagashima M, Genotype to Phenotype Japan C, Ito J, Sato K. Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect Dis.
2024;24(7):e416. doi: 10.1016/S1473-3099(24)00298-6. PubMed PMID: 38782005.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00298-6</ArticleId><ArticleId IdType="pubmed">38782005</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Franchini M, Casadevall A, Maggi F. An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2. Clin Microbiol Infect.
2024;30(8):999–1006. doi: 10.1016/j.cmi.2024.04.012. PubMed PMID: 38663655.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2024.04.012</ArticleId><ArticleId IdType="pubmed">38663655</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Diallo S, Rosenthal K, Ren K, Flores DJ, Dippel A, Oganesyan V, van Dyk N, Chen
X,Cantu E, Choudhary R, Sulikowski M, Adissu H, Chawla B, Kar S, Liu C, Dijokaite-Guraliuc A, Mongkolsapaya J, Rajan S, Loo YM, Beavon R, Webber C, Chang LJ, Thomas S, Clegg L, Zhang H, Screaton GR, Philbin N, Harre M, Selim A, Martinez-Alier N, Uriel A, Cohen TS, Perez JL, Esser MT, Blair W, Francica JR. AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults. Sci Transl Med.
2024;16(753):eado2817. doi: 10.1126/scitranslmed.ado2817. PubMed PMID: 38924429.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.ado2817</ArticleId><ArticleId IdType="pubmed">38924429</ArticleId></ArticleIdList></Reference><Reference><Citation>AstraZeneca. Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention. 2024.</Citation></Reference><Reference><Citation>Fact sheet for healthcare providers: Emergency Use Authorization of Pemgarda (pemivibart). Invivyd; 2024. Accessed March 25, 2024. In: Pemgarda, editor.: FDA.gov; 2024.</Citation></Reference><Reference><Citation>Cao Y, Jian F, Zhang Z, Yisimayi A, Hao X, Bao L, Yuan F, Yu Y, Du S, Wang J, Xiao T, Song W, Zhang Y, Liu P, An R, Wang P, Wang Y, Yang S, Niu X, Zhang Y, Gu Q, Shao F, Hu Y, Yin W, Zheng A, Wang Y, Qin C, Jin R, Xiao J, Xie XS. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep.
2022;41(12):111845. doi: 10.1016/j.celrep.2022.111845. PubMed PMID: 36493787; PMCID: PMC9712074.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111845</ArticleId><ArticleId IdType="pmc">PMC9712074</ArticleId><ArticleId IdType="pubmed">36493787</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, Wang P, Wang J, Liu J, Yu L, Niu X, Wang J, Wang Y, Shao F, Jin R, Wang Y, Cao Y. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect Dis.
2024;24(2):e70–e2. doi: 10.1016/S1473-3099(23)00744-2. PubMed PMID: 38109919.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00744-2</ArticleId><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Beijing Boren Hospital. Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19 [Internet]. ClinicalTrials.gov identifier: NCT123456. Available from: https://clinicaltrials.gov/study/NCT05675943.</Citation></Reference><Reference><Citation>Buchrieser J, Dufloo J, Hubert M, Monel B, Planas D, Rajah MM, Planchais C, Porrot F, Guivel-Benhassine F, Van der Werf S, Casartelli N, Mouquet H, Bruel T, Schwartz O. Syncytia formation by SARS-CoV-2-infected cells. EMBO J.
2020;39(23):e106267. doi: 10.15252/embj.2020106267. PubMed PMID: 33051876; PMCID: PMC7646020.
</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106267</ArticleId><ArticleId IdType="pmc">PMC7646020</ArticleId><ArticleId IdType="pubmed">33051876</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bol-land WH, Porrot F, Staropoli I, Lemoine F, Pere H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Marti-Carreras J, Cuypers L, Seve A, Hocqueloux L, Prazuck T, Rey FA, Simon-Loriere E, Bruel T, Mouquet H, Andre E, Schwartz O. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature.
2022;602(7898):671–5. doi: 10.1038/s41586-021-04389-z. PubMed PMID: 35016199.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C, Buchrieser J, Rajah MM, Bishop E, Albert M, Donati F, Prot M, Behillil S, Enouf V, Maquart M, Smati-Lafarge M, Varon E, Schortgen F, Yahyaoui L, Gonzalez M, De Seze J, Pere H, Veyer D, Seve A, Simon-Loriere E, Fafi-Kremer S, Stefic K, Mouquet H, Hocqueloux L, van der Werf S, Prazuck T, Schwartz O. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med.
2021;27(5):917–24. doi: 10.1038/s41591-021-01318-5. PubMed PMID: 33772244.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01318-5</ArticleId><ArticleId IdType="pubmed">33772244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I, Guivel-Benhassine F, Porrot F, Bolland WH, Nguyen Y, Casadevall M, Charre C, Pere H, Veyer D, Prot M, Baidaliuk A, Cuypers L, Planchais C, Mouquet H, Baele G, Mouthon L, Hocqueloux L, Simon-Loriere E, Andre E, Terrier B, Prazuck T, Schwartz O. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med.
2022;28(6):1297–302. doi: 10.1038/s41591-022-01792-5. PubMed PMID: 35322239; PMCID: 35322239.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01792-5</ArticleId><ArticleId IdType="pubmed">35322239</ArticleId></ArticleIdList></Reference><Reference><Citation>Planchais C, Fernandez I, Bruel T, de Melo GD, Prot M, Beretta M, Guardado-Calvo P, Dufloo J, Molinos-Albert LM, Backovic M, Chiaravalli J, Giraud E, Vesin B, Conquet L, Grzelak L, Planas D, Staropoli I, Guivel-Benhassine F, Hieu T, Boulle M, Cervantes-Gonzalez M, Ungeheuer MN, Charneau P, van der Werf S, Agou F, French CCSG, Group CS, Dimitrov JD, Simon-Loriere E, Bourhy H, Montagutelli X, Rey FA, Schwartz O, Mouquet H. Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. J Exp Med.
2022;219(7). doi: 10.1084/jem.20220638. PubMed PMID: 35704748; PMCID: PMC9206116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220638</ArticleId><ArticleId IdType="pmc">PMC9206116</ArticleId><ArticleId IdType="pubmed">35704748</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Chall.
2017;1(1):33–46. doi: 10.1002/gch2.1018. PubMed PMID: 31565258; PMCID: PMC6607375.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gch2.1018</ArticleId><ArticleId IdType="pmc">PMC6607375</ArticleId><ArticleId IdType="pubmed">31565258</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill.
2017;22(13):30494. doi: 10.2807/1560-7917.ES.2017.22.13.30494. PubMed PMID: 28382917; PMCID: PMC5388101.
</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.13.30494</ArticleId><ArticleId IdType="pmc">PMC5388101</ArticleId><ArticleId IdType="pubmed">28382917</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsueng G, Mullen JL, Alkuzweny M, Cano M, Rush B, Haag E, Lin J, Welzel DJ, Zhou X, Qian Z, Latif AA, Hufbauer E, Zeller M, Andersen KG, Wu C, Su AI, Gangavarapu K, Hughes LD. Outbreak.info Research Library: a standardized, searchable platform to discover and explore COVID-19 resources. Nat Methods.
2023;20(4):536–40. doi: 10.1038/s41592-023-01770-w. PubMed PMID: 36823331; PMCID: PMC10393269.
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-023-01770-w</ArticleId><ArticleId IdType="pmc">PMC10393269</ArticleId><ArticleId IdType="pubmed">36823331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Guo Y, Ho J, Ho DD. Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages. bioRxiv. 2024:2024.08.12.607496. doi: 10.1101/2024.08.12.607496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.08.12.607496</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>